INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 184 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,296,465 | -26.6% | 69,928 | -56.2% | 0.00% | -50.0% |
| Q2 2023 | $1,766,901 | +3.6% | 159,756 | +25.8% | 0.00% | 0.0% |
| Q1 2023 | $1,705,113 | -5.7% | 126,963 | -13.2% | 0.00% | 0.0% |
| Q4 2022 | $1,808,617 | +26.7% | 146,210 | +43.0% | 0.00% | 0.0% |
| Q3 2022 | $1,428,000 | +0.8% | 102,277 | -0.3% | 0.00% | +100.0% |
| Q2 2022 | $1,417,000 | -16.1% | 102,634 | -1.1% | 0.00% | 0.0% |
| Q1 2022 | $1,688,000 | +7.8% | 103,740 | +7.9% | 0.00% | 0.0% |
| Q4 2021 | $1,566,000 | +64.8% | 96,164 | +50.4% | 0.00% | 0.0% |
| Q3 2021 | $950,000 | -26.5% | 63,952 | -1.1% | 0.00% | 0.0% |
| Q2 2021 | $1,292,000 | -33.9% | 64,685 | -23.6% | 0.00% | 0.0% |
| Q1 2021 | $1,954,000 | -39.9% | 84,671 | -35.7% | 0.00% | -50.0% |
| Q4 2020 | $3,251,000 | -43.2% | 131,613 | -4.6% | 0.00% | -33.3% |
| Q3 2020 | $5,719,000 | -6.9% | 137,965 | +7.7% | 0.00% | -25.0% |
| Q2 2020 | $6,140,000 | -53.4% | 128,149 | -38.8% | 0.00% | -63.6% |
| Q1 2020 | $13,182,000 | -25.3% | 209,350 | +47.1% | 0.01% | -15.4% |
| Q4 2019 | $17,635,000 | +50.6% | 142,315 | -19.3% | 0.01% | +30.0% |
| Q3 2019 | $11,710,000 | -28.0% | 176,459 | -13.7% | 0.01% | -28.6% |
| Q2 2019 | $16,266,000 | +31.4% | 204,428 | +84.7% | 0.01% | +27.3% |
| Q1 2019 | $12,383,000 | +5.0% | 110,702 | -5.4% | 0.01% | -8.3% |
| Q4 2018 | $11,793,000 | -9.6% | 117,000 | +13.4% | 0.01% | 0.0% |
| Q3 2018 | $13,040,000 | +26.8% | 103,201 | -15.8% | 0.01% | +20.0% |
| Q2 2018 | $10,284,000 | +2.5% | 122,561 | -24.8% | 0.01% | +11.1% |
| Q1 2018 | $10,030,000 | +10.3% | 163,031 | +4.7% | 0.01% | +12.5% |
| Q4 2017 | $9,094,000 | -18.5% | 155,657 | -19.0% | 0.01% | -27.3% |
| Q3 2017 | $11,153,000 | -37.6% | 192,183 | +30.2% | 0.01% | -35.3% |
| Q2 2017 | $17,870,000 | -15.7% | 147,605 | -21.2% | 0.02% | -10.5% |
| Q1 2017 | $21,190,000 | +29.2% | 187,341 | +24.1% | 0.02% | +18.8% |
| Q4 2016 | $16,403,000 | -29.1% | 150,973 | +7.4% | 0.02% | -27.3% |
| Q3 2016 | $23,136,000 | +93.9% | 140,566 | +68.1% | 0.02% | +69.2% |
| Q2 2016 | $11,933,000 | +25.9% | 83,640 | +13.4% | 0.01% | +18.2% |
| Q1 2016 | $9,479,000 | +7.1% | 73,781 | +24.5% | 0.01% | +10.0% |
| Q4 2015 | $8,853,000 | -2.8% | 59,267 | +7.9% | 0.01% | -9.1% |
| Q3 2015 | $9,108,000 | -50.2% | 54,924 | -27.5% | 0.01% | -38.9% |
| Q2 2015 | $18,285,000 | -0.9% | 75,757 | +15.8% | 0.02% | -5.3% |
| Q1 2015 | $18,455,000 | +110.8% | 65,440 | +16.6% | 0.02% | +137.5% |
| Q4 2014 | $8,754,000 | -4.3% | 56,116 | +45.3% | 0.01% | +14.3% |
| Q3 2014 | $9,143,000 | +77.8% | 38,628 | +77.8% | 0.01% | +75.0% |
| Q2 2014 | $5,141,000 | +7.4% | 21,729 | +49.7% | 0.00% | -20.0% |
| Q1 2014 | $4,788,000 | +1333.5% | 14,517 | +196.7% | 0.01% | – |
| Q4 2013 | $334,000 | – | 4,893 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $14,787,000 | 2.73% |
| DeepCurrents Investment Group LLC | 416,800 | $9,620,000 | 0.33% |
| DUALITY ADVISERS, LP | 105,668 | $2,439,000 | 0.21% |
| EULAV Asset Management | 335,000 | $7,732,000 | 0.21% |
| Virtus ETF Advisers LLC | 19,375 | $447,000 | 0.19% |
| Hennion & Walsh Asset Management, Inc. | 135,214 | $3,121,000 | 0.19% |
| PDT Partners, LLC | 110,592 | $2,552,000 | 0.18% |
| KETTLE HILL CAPITAL MANAGEMENT, LLC | 70,256 | $1,622,000 | 0.16% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $3,896,000 | 0.12% |
| WOODWARD DIVERSIFIED CAPITAL, LLC | 8,939 | $206,000 | 0.12% |